DCx Biotherapeutics Corporation

DCx Biotherapeutics Corporation

Biotechnology Research

Harnessing the potential of next-gen antibody drug conjugates to improve patient outcomes

About us

Our vision is to develop a pipeline of 1st- in-class precision drug conjugates that are more efficacious and significantly less toxic than traditional antimitotic or topoisomerase inhibiting ADCs.

Website
www.dcxbio.com
Industry
Biotechnology Research
Company size
2-10 employees
Type
Privately Held
Founded
2024

Employees at DCx Biotherapeutics Corporation

Similar pages